Report details exciting immuno-oncology prospects in fight against cancer

11 January 2017

The American Association for Cancer Research (AACR) has reported that the overall cancer death rate in the USA is decreasing, and the number of cancer survivors is increasing, thanks in part to exciting new developments in immuno-oncology and other therapeutic areas.

The findings were outlined in the organization’s annual Cancer Progress Report, which summarizes ongoing challenges in oncology, therapeutic developments, and the clinical and economic impact of the disease.

Progress in immuno-oncology

Advances in the field of immuno-oncology have fueled excitement about possible future treatments in this area.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK